By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Route de Champ Colin, 18

Nyon     1260  Switzerland
Phone: 41-22-552-09-71 Fax: n/a


Elanix is a Swiss Life Science company dedicated to regenerative medicine using progenitor cells stored and expanded in its own GMP validated Master Cell Bank. Elanix is the sole owner of a set of skin progenitor cell lines that can be further multiplied generating over 35 billion of 10×10 cm advanced wound dressings without any further cell technology related costs. Elanix has the option to license to two patents invented by the founder during the tenure as a professor in the University Hospital of Lausanne, Switzerland (CHUV).




Founder and CSO: Lee Ann Laurent-Applegate

CEO: Tomas J. Svoboda


Please click here for Elanix Biotechnologies job opportunities.


Please click here for clinical trial information.

Key Statistics

Ownership: Public

Web Site: Elanix
Symbol: ELN


Company News
Elanix (ELN) Launches Adherence App For Gynrepair Women’s Intimate Health Cream 6/27/2017 11:28:55 AM
Elanix (ELN) Starts EU Commercialization Of Gynrepair Cream For Women’s Intimate Relief 5/31/2017 6:34:26 AM
Elanix (ELN) Signs Agreement With Apraxon To Establish European Logistics Center 4/21/2017 6:05:36 AM
Elanix (ELN) Acquires Third Cell Based Bioactive Cream Formulation With Potential To Alleviate A Significant Chronic Dermatological Condition 3/16/2017 6:44:09 AM
Elanix (ELN) Announces Non-Binding Letter Of Intent With Oxford MEstar Ltd. In Regard To Setting Up A JV To Market GynRepair In China 11/22/2016 9:19:34 AM
Elanix Technologies Strategic Partner, Transwell Biotechnology, Receives U.S. FDA Clearance For Phase I/II Clinical Trial Using Fibroblast Progenitors TWB-103 11/8/2016 10:15:01 AM
Elanix Technologies Signs Supply And Manufacturing Agreements With Sincopharm And Tec-Pharma For Production Of Medical Cosmetics Acquired From Repair-A 10/10/2016 12:23:34 PM